Zu-Chian Chiang | Biomedicine | Best Researcher Award

Posted on by Pencis

Dr. Zu-Chian Chiang | Biomedicine | Best Researcher Award

Fujian Normal University | China

Author Profile

Scopus

🔬 Dr. Zu-Chian Chiang, Ph.D.

Postdoctoral Fellow | Biomedical Research & Targeted Cancer Therapy Specialist 🧪🧬🎯
Fujian Normal University, Biomedical Research Center of Southern China

Dr. Zu-Chian Chiang is a distinguished Postdoctoral Fellow at the Biomedical Research Center of Southern China, Fujian Normal University, Qishan Campus, in Fuzhou, China. With a strong foundation in Materials and Chemical Engineering (Ph.D., National United University, Taiwan) and Chemistry (M.S., Tunghai University, Taiwan), Dr. Chiang has dedicated his academic journey to the intersection of materials science, chemistry, and biomedical innovation.

His research interests span a broad range of cutting-edge biomedical fields, including:
🔹 Functional peptide synthesis for cancer and bone tissue applications
🔹 Development of biomicro/macro-molecular complexes for regenerative medicine
🔹 Design of Antibody Drug Conjugates (ADCs) for targeted cancer therapy
🔹 Engineering of aptamers as blockers, agonists, or antagonists in cancer treatment

💡 Dr. Chiang has also contributed to academia through teaching roles, serving as a Teaching Assistant in Organic Chemistry and Chemical Engineering Thermodynamics at National United University.

🏆 Awards & Honors

  • 2020: Science and Technology Commissioner, Quanzhou, Fujian Province

  • 2017: Chairman Award, Miaoli Southeast Rotary Club, Rotary International Taiwan

  • 2016: Biotech Elite Training Reserve Program Awardee, National Taiwan University, Ministry of Science and Technology

🌐 Professional Affiliations & Contributions

  • Peer Reviewer, International Journal of Biological Macromolecules

  • Chief Club President (CP), Miaoli Xindong Satellite Rotary Club, Rotary International District 3501

  • Committee Member, Chinese Rotary Education Foundation (West District Chapter)

  • Member, Taiwan Biochemical Society 🧬

  • Member, Chinese Chemical Society ⚗️

  • Member, Chinese Society of Cell Biology 🔬

Dr. Chiang continues to blend his expertise in chemistry and biomedical engineering to push forward translational research, particularly in the field of cancer therapeutics and regenerative biomaterials.

🛡️ Conclusion

Dr. Zu-Chian Chiang stands at the forefront of interdisciplinary biomedical research, merging materials science, chemistry, and biotechnology to pioneer novel solutions in cancer therapy and regenerative medicine. His dedication to scientific advancement, combined with his active involvement in academic, professional, and community networks, highlights his role as a passionate innovator and collaborative leader in the global biomedical field. With a strong track record and a clear vision, Dr. Chiang continues to make impactful contributions that bridge the gap between cutting-edge research and clinical application. 🌍🔬💡

📊🔬NOTABLE PUBLICATION:

1. Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer In Vitro and In Vivo

Authors: Zu-Chian Chiang*, Shan Xu, Xiangqian Zhao, Min Liu*, Jizhen Lin*, Qi Chen*
Journal: Frontiers in Oncology
Year: 2022

2. Generation and Characterization of 7DC-DM1: A Non-Cleavable CD47-Targeting Antibody–Drug Conjugate with Antitumor Effects

Authors: Zu-Chian Chiang*, Shubin Fang, Yangkun Shen, Jizhen Lin, Qi Chen
Journal: International Journal of Biological Macromolecules
Year: 2025

3. Strengthening Effect of Thalidomide Combined with Anti-PD1 Antibody on Enhancing Immunity for Lung Cancer Therapy

Authors: Qing Liu, Zu-Chian Chiang#, Xiangxian Zhao, Dong-Ya Cui, Xinxin Li, Hao Chen, Fangyu Lin, Tao Jiang, Qi Chen, Xiaoyan Lin*
Journal: Current Pharmaceutical Biotechnology
Year: 2024

4. Preparation and Characterization of Antibody–Drug Conjugates Acting on HER2-Positive Cancer Cells

Authors: Zu-Chian Chiang, Yi-Kai Chiu, Cheng-Chung Lee, Yueh-Liang Tsou, Hong-Sen Chen, Horng-Ru Hsu, Tzung-Jie Yang
Journal: PLOS ONE
Year: 2020

Prof Dr. Tao Sun | Nucleic Acid Drug | Best Researcher Award

Posted on by Pencis

Prof Dr. Tao Sun | Nucleic Acid Drug | Best Researcher Award

Nankai University | China

Author Profile

Scopus

Orcid ID

📚 Prof. Tao Sun: Innovator in Oncology and Drug Development

🎓Position:

  • Professor and Doctoral Supervisor, College of Pharmacy, Nankai University, China 🎓

🌟Titles and Awards:

  • National Youth Talent 🌟
  • Winner of the Tianjin Distinguished Youth Scholar 🏆

🔬Research Focus:

  • Molecular mechanisms of malignant tumors 🧬
  • Drug development 💊
  • Pharmacology 🔬

📄Publications:

  • Over 40 papers in prestigious journals, including Advanced Materials, Science Translational Medicine, Hepatology, and Cancer Research, as the first or corresponding author. 📄

📜Patents and Approvals:

  • More than 20 authorized patents 📜
  • 3 new drug clinical approvals ✅

🧪Research Leadership:

  • Principal investigator of 8 major scientific research projects, including Major National Science and Technology Projects and general projects of the National Natural Science Foundation of China. 🧪

🥇Achievements in Education:

  • Instructed students to win the Gold Award in the China International College Students’ “Internet+” Innovation and Entrepreneurship Competition 🥇
  • Recipient of the “Top Ten Award of Scholarly Mentor and Beneficial Friend” at Nankai University 🎖
  • Second Prize winner of the Nankai University Teaching Achievement Award 🥈

💊Summary:

  • Prof. Tao Sun is a distinguished scholar and innovator at Nankai University, renowned for his contributions to oncology, drug development, and pharmacology. His prolific research, numerous patents, and leadership in significant scientific projects underscore his impact in the field. As an educator, he has been instrumental in guiding students to achieve excellence, earning recognition for his mentorship and teaching achievements. 🌟🔬💊

 

📊🔬Notable Publication:

 

Interaction between laminin-5γ2 and integrin β1 promotes the tumor budding of colorectal cancer via the activation of Yes-associated proteins

  • Authors: Zhou, B., Zong, S., Zhong, W., … Sun, T., Liu, Y.
    Journal: Oncogene
  • Year: 2020

 

Glycyrrhizic Acid-Induced Differentiation Repressed Stemness in Hepatocellular Carcinoma by Targeting c-Jun N-Terminal Kinase 1

  • Authors: Cai, S., Bi, Z., Bai, Y., … Liu, H., Yang, C.
    Journal: Frontiers in Oncology
  • Year: 2020

 

Twist1-YY1-p300 complex promotes the malignant progression of HCC through activation of miR-9 by forming phase-separated condensates at super-enhancers and relieved by metformin

  • Authors: Meng, J., Han, J., Wang, X., … Liu, H., Sun, T.
    Journal: Pharmacological Research
  • Year: 2023

 

Correction: Interaction between laminin-5γ2 and integrin β1 promotes the tumor budding of colorectal cancer via the activation of Yes-associated proteins

  • Authors: Zhou, B., Zong, S., Zhong, W., … Sun, T., Liu, Y.
    Journal: Oncogene
  • Year: 2020

 

YY1 complex promotes quaking expression via super-enhancer binding during EMT of hepatocellular carcinoma

  • Authors: Han, J., Meng, J., Chen, S., … Sun, T., Yang, C.
    Journal: Cancer Research
  • Year: 2019

Assist Prof Dr Matthias Bartneck | Cancer Therapy | Best Researcher Award

Posted on by Pencis

Assist Prof Dr Matthias Bartneck | Cancer Therapy | Best Researcher Award 

RWTH Aachen University | Germany

AUTHOR PROFILE

Scopus

Google Scholar

Orcid ID

EARLY ACADEMIC PURSUITS

Priv.-Doz. Dr. rer. nat. Matthias Bartneck embarked on his academic journey with a diploma in Biology from the University of Bielefeld (2001-2006). His diploma thesis focused on gene expression and metabolite profiling of human primary mamma carcinomas, under the supervision of Dr. Anke Becker. He continued his academic pursuits with a Doctor of Natural Sciences degree from RWTH Aachen (2007-2010), where his research centered on the interactions of human primary immune cells with various nanomaterials. This work was supervised by Prof. Gabriele Zwadlo-Klarwasser.

PROFESSIONAL ENDEAVORS

Dr. Bartneck’s professional career has been marked by a series of significant positions and collaborations. He has been employed at the Medical Faculty 10, Gastroenterology, and Faculty 1 Leibniz Institute for Interactive Materials DWI/RWTH Institute for Technical and Macromolecular Chemistry (ITMC) since 2023. He has also served as a guest lecturer at the Max Planck Research Training School Matter to Life. From 2018 to 2022, he was a lecturer at the Center for Functional Magnetic Materials, Immanuel Kant Baltic Federal University in Kaliningrad, Russia. Additionally, Dr. Bartneck has been a group leader at the Medical Faculty, Medical Clinic III, RWTH Aachen since 2014, focusing on immunomodulatory nanomedicine for inflammatory diseases and cancer.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER THERAPY

Dr. Bartneck’s research has significantly advanced the fields of gastroenterology, hepatology, and nanomedicine. His work has delved into the development of novel nanocarriers for treating liver diseases and cancer, as well as the modulation of immune cell migration and activation in inflammatory diseases. His research has been supported by substantial funding, including grants from the German Research Foundation (DFG) and the Wilhelm Sander Foundation. His contributions include over 61 publications, 18 as the first author and 4 as the last author, along with 7 book chapters and 9 reviews.

CITATIONS

  • Zitate           4439
  • h-index        35
  • i10-index     49

IMPACT AND INFLUENCE

Dr. Bartneck’s research has had a profound impact on the scientific community, evidenced by a total of 3764 citations and an H-index of 32. His expertise in immunomodulatory nanomedicine has led to collaborations with prestigious institutions and industry partners, including Bayer Healthcare, Novartis, and Precision Nanosystems. His work has been recognized with several fellowships and awards, such as the Young Investigator Award from the European Association for the Study of the Liver (EASL).

ACADEMIC CITES

Dr. Bartneck has held numerous academic positions and provided significant contributions to teaching and mentoring. He has supervised a wide range of students, from bachelor to doctoral levels, across multiple disciplines including medicine, chemistry, and biology. His teaching roles have included lectures and practical courses in materials science, blood and defense, and inflammation at RWTH Aachen.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Bartneck’s legacy is marked by his interdisciplinary approach and dedication to advancing nanomedicine and immunology. He has secured research funds exceeding €1,500,000 in 2022 alone for the development of novel lipid-based nucleic acid therapeutics. His future contributions are expected to further enhance the understanding and treatment of inflammation-associated diseases and cancer. His continued collaborations with international academic and industry partners underscore his commitment to advancing scientific knowledge and innovation.

NOTABLE PUBLICATION:

Citation: 08         Year: 2022

Citation: 01        Year: 2023